1-3 of 3
Arooj Khan
Close
Sort by
Journal Articles

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Donna E. Reece, MD, Esther Masih-Khan, PhD, Arooj Khan, Saima Dean, Sharon Fung, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Suzanne Trudel, MD, MSC, FRCPC
Journal: Blood
Blood (2010) 116 (21): 3055.
https://doi.org/10.1182/blood.V116.21.3055.3055
Published: 2010
Journal Articles

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

Donna E. Reece, MD, FRCPC, Esther Masih-Khan, PhD, Arooj Khan, Saima Dean, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Suzanne Trudel
Journal: Blood
Blood (2009) 114 (22): 1874.
https://doi.org/10.1182/blood.V114.22.1874.1874
Published: 2009
Journal Articles

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid ® ) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

Donna E. Reece, MD, Esther Masih-Khan, Arooj Khan, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, Joseph R. Mikhael, MD, Suzanne Trudel, MD
Journal: Blood
Blood (2008) 112 (11): 1723.
https://doi.org/10.1182/blood.V112.11.1723.1723
Published: 2008